Clinical evidence

The incidence of sepsis is increasing by 8 % per year and the mortality rate due to sepsis by 1.5 % per year. Sepsis patients now represent 10 to 16 % of the total cost of intensive care1,2. The development of new treatment methods is unquestionably crucial, for both humanitarian and economical reasons.

Postmortem studies have shown that persistent infectious foci can be found in 80 % of patients succumbing to sepsis in the ICU. The development of septic shock was preceding death in almost all the patients3. The optimal outcome of a treatment for gram-negative sepsis would therefore be both reduced mortality and reduced morbidity. However, no specific medical treatment is currently available.

The Alteco® LPS Adsorber has the capacity to significantly reduce endotoxemia when used in hemoperfusion of patients with gram-negative sepsis. This is beneficial to the patients as it dramatically reduces the effects of gram-negative sepsis, such as cardiorespiratory dysfunction and the release of pro- and anti-inflammatory mediators.

More than 2000 treatments have been carried out worldwide using the Alteco® LPS Adsorber. The clinical reports and published data on the efficacy of the Alteco® LPS Adsorber to remove endotoxin from the blood as well as to improve the cardiorespiratory function in patients suffering from severe gram-negative sepsis and septic shock, are unequivocal4,5.

1. Angus, D.C., et al., 2001. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med, 29/7: 1303‒1310

2. Martin, G.S., et al., 2003. The epidemiology of sepsis in the United States from 1979 through 2000. New Engl J Med, 348/16: 1546‒54

3. Torgersen, C., et al., 2009. Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg, 108/6: 1841‒7.

4. Ala-Kokko, T.I., et al., 2011. A New Endotoxin Adsorber in Septic Shock: Observational Case Series. Blood Purif, 32: 303‒309

5. Adamik, B. et al., 2015. Endotoxin Elimination in Patients with Septic Shock: An Observation Study. Arch Immunol. Ther. Exp. (online publ)

© Alteco Medical AB 2013. All rights reserved • Produced by Publiciteta&Co